These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Seed implant retention score predicts the risk of prolonged urinary retention after prostate brachytherapy. Lee HK; Adams MT; Shi Q; Basillote J; Lamonica J; Miranda L; Motta J Int J Radiat Oncol Biol Phys; 2010 Apr; 76(5):1445-9. PubMed ID: 19553032 [TBL] [Abstract][Full Text] [Related]
8. Relationship of the International Prostate Symptom score with urinary flow studies, and catheterization rates following 125I prostate brachytherapy. Martens C; Pond G; Webster D; McLean M; Gillan C; Crook J Brachytherapy; 2006; 5(1):9-13. PubMed ID: 16563992 [TBL] [Abstract][Full Text] [Related]
9. Corticosteroid use after prostate brachytherapy reduces the risk of acute urinary retention. Sacco DE; Daller M; Grocela JA; Babayan RK; Zietman AL BJU Int; 2003 Mar; 91(4):345-9. PubMed ID: 12603412 [TBL] [Abstract][Full Text] [Related]
10. Factors associated with the frequency of self-intermittent catheterization after prostate brachytherapy. Schwartz DJ; Schild SE; Wong WW; Vora SA Int J Radiat Oncol Biol Phys; 2005 Jan; 61(1):60-3. PubMed ID: 15629594 [TBL] [Abstract][Full Text] [Related]
11. The effect of hormonal manipulation on urinary function following permanent prostate brachytherapy. Merrick GS; Butler WM; Wallner KE; Murray B; Allen Z; Lief JH; Galbreath RW Brachytherapy; 2004; 3(1):22-9. PubMed ID: 15110310 [TBL] [Abstract][Full Text] [Related]
12. The impact of acute urinary retention after iodine-125 prostate brachytherapy on health-related quality of life. Roeloffzen EM; Hinnen KA; Battermann JJ; Monninkhof EM; van Roermund JG; van Gellekom MP; Frank SJ; van Vulpen M Int J Radiat Oncol Biol Phys; 2010 Aug; 77(5):1322-8. PubMed ID: 19939578 [TBL] [Abstract][Full Text] [Related]
13. Urinary and rectal complications of contemporary permanent transperineal brachytherapy for prostate carcinoma with or without external beam radiation therapy. Sarosdy MF Cancer; 2004 Aug; 101(4):754-60. PubMed ID: 15305406 [TBL] [Abstract][Full Text] [Related]
15. Prophylactic tamsulosin (Flomax) in patients undergoing prostate 125I brachytherapy for prostate carcinoma: final report of a double-blind placebo-controlled randomized study. Elshaikh MA; Ulchaker JC; Reddy CA; Angermeier KW; Klein EA; Chehade N; Altman A; Ciezki JP Int J Radiat Oncol Biol Phys; 2005 May; 62(1):164-9. PubMed ID: 15850917 [TBL] [Abstract][Full Text] [Related]
16. Predictive factors of urinary retention following prostate brachytherapy. Bucci J; Morris WJ; Keyes M; Spadinger I; Sidhu S; Moravan V Int J Radiat Oncol Biol Phys; 2002 May; 53(1):91-8. PubMed ID: 12007946 [TBL] [Abstract][Full Text] [Related]
17. Severity categories of the International Prostate Symptom Score before, and urinary morbidity after, permanent prostate brachytherapy. Gutman S; Merrick GS; Butler WM; Wallner KE; Allen Z; Galbreath RW; Adamovich E BJU Int; 2006 Jan; 97(1):62-8. PubMed ID: 16336330 [TBL] [Abstract][Full Text] [Related]
18. A nomogram to compensate for intraoperative prostate edema during transperineal brachytherapy. Potters L; Wang XH; Yamada Y Tech Urol; 2000 Jun; 6(2):99-103. PubMed ID: 10798808 [TBL] [Abstract][Full Text] [Related]
19. A phase III randomized trial of the timing of meloxicam with iodine-125 prostate brachytherapy. Crook J; Patil N; Wallace K; Borg J; Zhou D; Ma C; Pond G Int J Radiat Oncol Biol Phys; 2010 Jun; 77(2):496-501. PubMed ID: 20350785 [TBL] [Abstract][Full Text] [Related]